Screener / SEC EDGAR /CIK 0001607678 /10-K filed Feb 11, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Viking Therapeutics, Inc. VKTX

Compare with peers Embed
Earnings releases

Latest results release: Oct 28, 2026

8-K item 2.02, exhibit 99

What VKTX's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 28, 2026 · EX-99.1

Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides

Open on SEC

Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

--VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance --

-- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated --

Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, October 28, 2026-- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Third Quarter Ended September 30, 2026, and Other Recent Events: “During the third quarter, Viking continued to advance and expand development activities in its obesity franchise. We recently announced the initiation of the SUNRISE Phase 3 program with the oral tablet formulation of VK2735, representing the third and fourth registration trials to be underway. The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation and we are excited to have these important clinical trials underway. In the third quarter we also announced positive results from our initial VK2735 dose-ranging maintenance study. These results demonstrated an impressive maintenance effect, excellent tolerability, and serve to further establish VK2735 as a differentiated potential treatment option for patients with obesity. Following the successful initial readout, we announced another milestone with the initiation of Part 2 of the maintenance study. As with Part 1, subjects will transition from a weekly induction period toa range of VK2735 maintenance options

including daily oral doses, every-other-week subcutaneous doses, monthly subcutaneous doses, orplacebo. The potential availability of both a tablet and a subcutaneous formulation, across a variety of dosing regimens, will offer unmatched optionality and flexibility to best support a personalized and sustainable weight loss journey. Also,during the quarter, the Phase 1 study of ourdual amylin and calcitonin receptoragonist VK3019continued to advance. Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027. To support our robust pipeline, as well as the activities related to the potential commercial launch of VK2735, during the quarter the company successfully closedconcurrent upsized public offerings of common stock and convertible senior notes, resulting in a strong quarter-end cash balance of $960 million. This provides the company with the runway to execute multiple Phase 3 trials and build the infrastructure to execute a strong and effective commercial strategy.” Pipeline and Recent Corporate Highlights Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Continue to Advance. VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, in development for the potential treatment of obesity and other metabolic disorders. Top-line data from the company’s prior Phase 2 VENTURE study of VK2735 in adults with obesity demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% after 13 weekly doses, with no signs of plateau. The VENTURE study also showed VK2735 to be safe and well tolerated through 13 weeks of dosing, with the majority of treatment emergent adverse events characterized as mild or moderate, and resolving quickly.

Based on the positive findings from the Phase 2 VENTURE study, and subsequent feedback from the U.S. Food and Drug Administration (FDA), the company advanced the subcutaneous formulation of VK2735 into Phase 3 development, initiating theVANQUISH Phase 3 registration program in June of last year. The VANQUISH program consists of two clinical trials: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.

The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation. The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation. Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.

The primary endpoint of the VANQUISH trials is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve at least 5%, 10%, 15% and 20% weight loss. Each study will include an extension portion allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period, including patients who were randomized to placebo for the initial 78-week treatment period.

VANQUISH Extension Studies to Commence in 1Q27. Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks. The extension studies will provide important long-term safety and efficacy data and afford subjects the opportunity to continue receiving VK2735 upon completion of the primary dosing periods. In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.

SUNRISE Oral Phase 3 VK2735 Program Initiated; SUNRISE 1 & 2 Trials Underway. In addition to its subcutaneous formulation, Viking is also advancing an oral tablet formulation of VK2735. If successful, the tablet formulation is positioned to become the first oral dual GLP-1/GIP agonist to reach the market. The company believes the availability of both oral and injectable formulations is a key differentiating feature of VK2735, as no other dual or triple agonist is currently available in both formulations. Importantly, using the same active ingredient across formulations may increase treatment adherence by reducing the risk of unexpected side effects compared with switching between therapies that do not share the same active agent. Viking believes the availability of both a tablet and a subcutaneous formulation will offer much needed optionality, flexibility and convenience to best support a personalized and sustainable weight loss journey - from the induction phase of weight loss through long-term weight management.

As with the company’s subcutaneous studies to date, thePhase 1 and Phase 2 trialsof Viking’s oral tablet formulation of VK2735successfully achieved their primary and secondary objectives. The Phase 2 VENTURE Oral Dosing study of VK2735 evaluatedonce daily doses of the tablet formulation. Top-line results demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 12.2% from baseline. Up to 80% of subjects in VK2735 treatment groups achieved at least 10% weight loss after 13 weeks, compared with only 5% of placebo treated subjects.The tablet formulation also demonstrated encouraging safety and tolerability through 13 weeks of daily dosing. The vast majority of drug-related treatment-emergent adverse events were characterized as mild or moderate, with no meaningful difference in gastrointestinal (GI)-related adverse events between subjects treated with VK2735 and placebo.

Earlier this month, the company announced the initiation of the SUNRISE Phase 3 registration program evaluating oral VK2735.The SUNRISE program includes two studies: SUNRISE-1 in adults with obesity and SUNRISE-2 in obese or overweight adults with type 2 diabetes. Each study is a randomized, double-blind, placebo- controlled, multicenter trial designed to assess the efficacy and safety of oral VK2735, with patients receiving once-daily doses for 68 weeks. SUNRISE-1 and SUNRISE-2 are each targeting enrollment of 560 adults. Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.

Viking is very pleased to have these important trials underway, as it believes oral VK2735 may represent another differentiated and high value treatment option for patients and physicians alike.

Positive Top-Line Results Announced for Part 1 of VK2735 Maintenance Dosing Study. Based on VK2735's promising efficacy and differentiated pharmacokinetic (PK) profile, the company is evaluating a range of novel dosing regimens for both the induction and the long-term maintenance of weight loss. Providing flexible options for long-term therapy, including lower dosing and less frequent administration, may improve treatment persistence following achievement of individual weight loss goals. In addition, affording patients the option to remain on the same therapeutic compound, in either a tablet or an injectable form, throughout their treatment journey may reduce the potential for undesired side effects compared with options that involve switching between different therapeutic agents. The company believes this may also lead to improved adherence to therapy and increase the probability of realizing the long-term benefits of weight loss such as reduced cardiovascular risks, improved physical function and enhanced quality of life.

In the third quarter the company reported positive results from Part 1 of a two- partrange-finding study. This study, which was designed to explore a variety of maintenance dosing regimens, demonstrated VK2735’s ability not only to achieve significant weight loss during the induction phase, but to also maintain a high percentage of the initial weight loss long-term using lower and less frequent dosing regimens.

Part 1 of the maintenance study was focused on subcutaneous dosing. The novel design incorporated multiple parts– a 21-week induction period, a 12-week maintenance period evaluating monthly or every-other-week dosing, and a 33-week dosing period utilizing a 17.5 mg weekly dose. A total of 180 subjects were randomized across 11 treatment groups. Subjects were required to have a BMI ≥30 kg/m2but no other comorbidities. Induction doses ranged from 15.0 mg to 22.5 mg per week, or placebo, administered once weekly by subcutaneous injection for 21 weeks. Following the 21-week induction period, subjects were transitioned to a range of subcutaneous maintenance regimens, or placebo, for an additional 12 weeks.

Through the initial 21 weeks of weekly dosing, robust weight loss was observed at all dose levels, with no signs of plateau. Week 21 weight loss ranged from approximately 16% to approximately 19% compared with approximately 0% for placebo. All doses clearly separated from placebo starting at Week 4, with p-values at each dosing level less than 0.0001 compared with placebo. Among treated subjects, 98% achieved 5% weight loss, 90% achieved 10%, 65% achieved 15%, and 32% achieved 20% weight loss. This compares well with the placebo cohort, for which only 13% achieved 5% weight loss and none achieved 10%, 15% or 20% weight loss at Week 21. Based on the weight loss trajectories among VK2735-treated subjects at Week 21, the company believes that further weight loss is likely to be observed with continued dosing.

Following the 21-week induction phase of the study, subjects were transitioned from weekly dosing to every-other-week or monthly dosing for an additional 12 weeks. Among subjects dosed every-other-week, mean weight loss retained at Week 33 ranged from 83% to 97%, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs. placebo. Among subjects transitioned to monthly dosing, mean weight loss retained at Week 33 ranged from 82% to 90%, compared with 61% for placebo, with p-values less than 0.01 for each cohort vs. placebo. The significant reduction in weight rebound compared with placebo under either regimen demonstrated a compelling maintenance signal, supporting the concept of less frequent dosing as a potentially viable regimen for long-term weight management.

The maintenance study also incorporated an exploratory cohort where subjects were maintained on a 17.5 mg weekly dose for the entire 33-week treatment window. These participants demonstrated continued weight loss throughout the 33 week study period, reaching approximately 22% from baseline. No plateau was observed, suggesting further weight loss might be expected with continued dosing.

This study also demonstrated a favorable tolerability profile and low rate of discontinuations. During the 21 week induction period, common GI adverse events such as nausea, vomiting, diarrhea, and constipation were consistent with those observed in the company’s prior Phase 2 VENTURE study. This is of particular interest as these subjects were titrated faster (every two weeks) compared with the slower titration schedule (every three weeks) used in the VENTURE study.

During the maintenance period of this study, following the transition to every- other-week or monthly dosing, an encouraging tolerability profile was also observed. Treatment emergent adverse events were similar to placebo, and GI- related adverse events were low and generally no different from placebo. These data suggest that despite a gap of up to four weeks between doses, these participants did not resensitize to GI adverse events such as nausea or vomiting. This supports the company’s view that VK2735’s differentiated PK profile, with an extended half-life and excellent long-term exposures, may provide for greater flexibility in dosing compared with existing options.

The company believes these results demonstrated a credible maintenance effect, a key objective of the study. Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027. ╔═ § ══════════════════════════════════════════════════════════════════════════╗ ║ ║ ║ Part 2 Maintenance Dosing Study Initiated, to Evaluate Oral and Additional ║ ║ Subcutaneous Regimens. ║ ║ ║ ╚══════════════════════════════════════════════════════════════════════════════╝ Following the successful completion of the first part of the maintenance dosing study, the company recently initiated Part 2 of this study, designed to evaluate a range of oral maintenance regimens, along with select subcutaneous maintenance doses. Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity(BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1, all

participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.

The company expects the results from Part 2 of this study to be available in 2027.

Phase 1 Single Ascending Dose Study of Amylin Agonist VK3019 Nearing Completion. VK3019 is an investigational dual amylin and calcitonin receptor agonist (DACRA) in development for the potential treatment of obesity. P reclinical data for this program showed robust effects on body weight, food intake, and metabolism in healthy rats, diet-induced obese mice, and obese primates compared to control-treated animals.

During the second quarter, the company initiateda Phase 1 single ascending dose (SAD) clinical trialevaluating VK3019.The Phase 1 trial is a randomized, double- blind, placebo-controlled SAD study in healthy adults with BMI ≥27. The primary objectives of the study include an evaluation of the safety, tolerability, and pharmacokinetics of VK3019 following administration of single subcutaneous doses. Exploratory pharmacodynamic assessments include evaluations of changes in body weight after a single-dose administration.

The company expects to complete the SAD study later this quarter and initiate a 4 week multiple ascending dose (MAD) study of VK3019 in 1Q27.

The addition of VK3019 to Viking’s clinical pipeline represents an important expansion of the company’s obesity franchise and further illustrates Viking’s commitment to treating obesity first with the goal of helping patients achieve and maintain a weight that will allow them to improve their overall health and quality of life.

Strong Quarter-End Cash Position of $960 Million Provides Resources to Execute Multiple Long-Term Objectives . In September, Viking successfully closed concurrent upsized public offerings of common stock and convertible senior notes, resulting in gross proceeds to the company of approximately $575.0 million. Following completion of the offering, at the end of the third quarter the company held $960 million in cash, cash equivalents and short-term investments. In addition to providing the runway needed to reach important milestones, including completion of the company’s ongoing Phase 3 obesity trials, and the development of earlier stage programs, these resources will support the company’s growing commercial operations, infrastructure and plans as it prepares for the potential commercial launch of VK2735.

Viking plans to make the following presentations at scientific conferences in the fourth quarter: ObesityWeek; November 14 – 17, 2026 - Washington, D.C:

VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics Saturday, November 14,2026, 7:30 pm - 8:30 pm ET

Poster presentation Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study Sunday, November 15, 2026, 2:30 pm - 3:30 pm ET Poster presentation Upcoming Investor Events Viking management will participate in the following upcoming investor events:

Third Quarter ended September 30, 2026, and 2025 Research and development expenses were $166.8 million for the three months ended September 30, 2026, compared to $90.0 million for the same period in 2025. The increase was primarily due to increased expenses related to planned and ongoing clinical studies, manufacturing for the company’s drug candidates, stock-based compensation, salaries and benefits and third-party consultants, partially offset by decreased expenses related to preclinical studies.

General and administrative expenses were $20.3 million for the three months ended September 30, 2026, compared to $8.6 million for the same period in 2025. The increase was primarily due to increased expenses related to legal and patent services, third-party consultants, stock-based compensation, and salaries and benefits. These increases reflect the company’s rapid overall growth compared with the same period in 2025.

For the three months ended September 30, 2026, Viking reported a net loss of $183.2 million, or $1.55 per share, compared to a net loss of $90.8 million, or $0.81 per share, in the corresponding period in 2025. The increase in net loss for the three months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025. Nine Months ended September 30, 2026, and 2025 Research and development expenses were $432.7 million for the nine months ended September 30, 2026, compared to $191.5 million for the same period in 2025. The increase was primarily due to increased expenses related to planned and ongoing clinical studies, stock-based compensation, manufacturing for the company’s drug candidates, salaries and benefits, and third-party consultants, partially offset by decreased expenses related to preclinical studies.

General and administrative expenses were $51.1 million for the nine months ended September 30, 2026, compared to $37.1 million for the same period in 2025. The increase was primarily due to increased expenses related to third-party consultants, legal and patent services, and salaries and benefits, partially offset by decreased expenses related to stock-based compensation. These increases reflect the company’s rapid overall growth compared with the same period in 2025.

For the nine months ended September 30, 2026, Viking reported a net loss of $469.5 million, or $4.03 per share, compared to a net loss of $202.0 million, or $1.80 per share, in the corresponding period in 2025. The increase in net loss for the nine months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025. Balance Sheet as of September 30, 2026 At September 30, 2026, Viking held cash, cash equivalents, and short-term investments of $960million, compared to $706 million as of December 31, 2025. This balance includes the aggregate net proceeds of approximately $550 million from the company’s recent financing. Conference Call Management will host a conference call to discuss Viking's third quarter 2026 financial results today at 4:30 pm Eastern. To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 4, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID #1882451. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at https://ir.vikingtherapeutics.com/webcasts-presentations. An archive of the webcast will also be available on the Webcasts page of Viking's website for 30 days. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).

For more information about Viking Therapeutics, please visitwww.vikingtherapeutics.com. Forward-Looking Statements This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward- looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product

candidate development activities and clinical trials, including those for VK2735, VK3019, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law. Viking Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) (Unaudited)

Viking Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts)

September December 30, 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Unaudited Assets Current assets: Cash and cash $ 677,609 $ 165,810 equivalents Short-term investments 282,204 539,929 – available-… Prepaid clinical trial and 10,008 8,053 preclinical study costs Prepaid expenses and other 3,178 1,806 current assets Total current 972,999 715,598 assets Right-of-u… 3,853 85 assets Restricted 202 — cash Deposits 113 46 Total $ 977,167 $ 715,729 assets Liabilities and stockholde… equity Current liabilitie… Accounts $ 82,134 $ 53,251 payable Other accrued 51,739 23,279 liabilities Lease liability, 24 137 current Total current 133,897 76,667 liabilities Lease liability, net of 4,014 — current portion Convertible 250,656 — Notes Total long-term 254,670 — liabilities Total 388,567 76,667 liabilities Commitments and contingenc… Stockholde… equity: Preferred stock, $0.00001 par value: 10,000,000 shares authorized at September 30, 2026 and December — — 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 Common stock, $0.00001 par value: 300,000,000 shares authorized at September 30, 2026 and December 31, 2025; 1 1 127,521,229 shares issued and outstanding at September 30, 2026 and 114,793,067 shares issued and outstanding at December 31, 2025 Additional paid-in 1,907,376 1,486,229 capital Accumulated (1,317,079 ) (847,546 ) deficit Accumulated other comprehens… (1,698 ) 378 (loss) gain Total stockholde… 588,600 639,062 equity Total liabilities and $ 977,167 $ 715,729 stockholde… equity

Full text with the tables
                                                                    Exhibit 99.1
 Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides  
                                Corporate Update                                
                                                                                
--VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance
                                       --                                       
                                                                                
             -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated --             
                                                                                
-- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part
                              2 Study Initiated --                              
                                                                                
      -- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion --       
                                                                                
             -- Strong Quarter-End Cash Position of $960 Million--              
                                                                                
                Conference call scheduled for 4:30 p.m. ET today                
SAN DIEGO, October 28, 2026-- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX),
a clinical-stage biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, today announced its financial
results for the third quarter and nine months ended September 30, 2026, and
provided an update on its clinical pipeline and other corporate developments.
Highlights from the Third Quarter Ended September 30, 2026, and Other Recent    
Events:                                                                         
“During the third quarter, Viking continued to advance and expand development
activities in its obesity franchise. We recently announced the initiation of the
SUNRISE Phase 3 program with the oral tablet formulation of VK2735, representing
the third and fourth registration trials to be underway. The SUNRISE oral Phase
3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating
the subcutaneous formulation and we are excited to have these important clinical
trials underway. In the third quarter we also announced positive results from
our initial VK2735 dose-ranging maintenance study. These results demonstrated an
impressive maintenance effect, excellent tolerability, and serve to further
establish VK2735 as a differentiated potential treatment option for patients
with obesity. Following the successful initial readout, we announced another
milestone with the initiation of Part 2 of the maintenance study. As with Part
1, subjects will transition from a weekly induction period toa range of VK2735
maintenance options

including daily oral doses, every-other-week subcutaneous doses, monthly
subcutaneous doses, orplacebo. The potential availability of both a tablet and a
subcutaneous formulation, across a variety of dosing regimens, will offer
unmatched optionality and flexibility to best support a personalized and
sustainable weight loss journey. Also,during the quarter, the Phase 1 study of
ourdual amylin and calcitonin receptoragonist VK3019continued to advance. Upon
completion, we expect to initiate a 28-day multiple ascending dose study of
VK3019 in the first quarter of 2027. To support our robust pipeline, as well as
the activities related to the potential commercial launch of VK2735, during the
quarter the company successfully closedconcurrent upsized public offerings of
common stock and convertible senior notes, resulting in a strong quarter-end
cash balance of $960 million. This provides the company with the runway to
execute multiple Phase 3 trials and build the infrastructure to execute a strong
and effective commercial strategy.”
Pipeline and Recent Corporate Highlights                                        
Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Continue to
Advance. VK2735 is a wholly owned long-acting dual agonist of the glucagon like
peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic
polypeptide, or GIP receptor, in development for the potential treatment of
obesity and other metabolic disorders. Top-line data from the company’s prior
Phase 2 VENTURE study of VK2735 in adults with obesity demonstrated
statistically significant reductions in mean body weight from baseline, ranging
up to 14.7% after 13 weekly doses, with no signs of plateau. The VENTURE study
also showed VK2735 to be safe and well tolerated through 13 weeks of dosing,
with the majority of treatment emergent adverse events characterized as mild or
moderate, and resolving quickly.

Based on the positive findings from the Phase 2 VENTURE study, and subsequent
feedback from the U.S. Food and Drug Administration (FDA), the company advanced
the subcutaneous formulation of VK2735 into Phase 3 development, initiating
theVANQUISH Phase 3 registration program in June of last year. The VANQUISH
program consists of two clinical trials: VANQUISH-1 in adults with obesity and
VANQUISH-2 in adults with obesity and type 2 diabetes. Each study is a
randomized, double-blind, placebo-controlled, multicenter trial designed to
assess the efficacy and safety of VK2735 administered by subcutaneous injection
once weekly for 78 weeks.

The VANQUISH-1 study enrolled approximately 4,500 patients within approximately
five months of initiation. The VANQUISH-2 study enrolled approximately 1,000
patients within approximately 9 months of initiation. Participants in each trial
have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.

The primary endpoint of the VANQUISH trials is the percent change in body weight
from baseline for participants receiving VK2735 as compared to placebo after 78
weeks of treatment. Secondary and exploratory endpoints will evaluate a range of
additional safety and efficacy measures, including the percentage of patients
who achieve at least 5%, 10%, 15% and 20% weight loss. Each study will include
an extension portion allowing participants the opportunity to continue receiving
treatment following completion of the primary dosing period, including patients
who were randomized to placebo for the initial 78-week treatment period.

During the third quarter, both VANQUISH studies continued to advance on track.
The company expects these studies to be completed in 2027.

VANQUISH Extension Studies to Commence in 1Q27. Following completion of the
78-week treatment period in both VANQUISH studies, participants are eligible to
enroll in extension studies, enabling them to continue their treatment for up to
an additional 52 weeks. The extension studies will provide important long-term
safety and efficacy data and afford subjects the opportunity to continue
receiving VK2735 upon completion of the primary dosing periods. In addition, the
VANQUISH-1 extension study will include certain less-frequent dosing regimens,
including every-other-week and monthly administration. The company anticipates
the results of the extension studies to be available in 2028.

SUNRISE Oral Phase 3 VK2735 Program Initiated; SUNRISE 1 & 2 Trials Underway. In
addition to its subcutaneous formulation, Viking is also advancing an oral
tablet formulation of VK2735. If successful, the tablet formulation is
positioned to become the first oral dual GLP-1/GIP agonist to reach the market.
The company believes the availability of both oral and injectable formulations
is a key differentiating feature of VK2735, as no other dual or triple agonist
is currently available in both formulations. Importantly, using the same active
ingredient across formulations may increase treatment adherence by reducing the
risk of unexpected side effects compared with switching between therapies that
do not share the same active agent. Viking believes the availability of both a
tablet and a subcutaneous formulation will offer much needed optionality,
flexibility and convenience to best support a personalized and sustainable
weight loss journey - from the induction phase of weight loss through long-term
weight management.

As with the company’s subcutaneous studies to date, thePhase 1 and Phase 2
trialsof Viking’s oral tablet formulation of VK2735successfully achieved their
primary and secondary objectives. The Phase 2 VENTURE Oral Dosing study of
VK2735 evaluatedonce daily doses of the tablet formulation. Top-line results
demonstrated statistically significant reductions in mean body weight after 13
weeks, ranging up to 12.2% from baseline. Up to 80% of subjects in VK2735
treatment groups achieved at least 10% weight loss after 13 weeks, compared with
only 5% of placebo treated subjects.The tablet formulation also demonstrated
encouraging safety and tolerability through 13 weeks of daily dosing. The vast
majority of drug-related treatment-emergent adverse events were characterized as
mild or moderate, with no meaningful difference in gastrointestinal (GI)-related
adverse events between subjects treated with VK2735 and placebo.

Earlier this month, the company announced the initiation of the SUNRISE Phase 3
registration program evaluating oral VK2735.The SUNRISE program includes two
studies: SUNRISE-1 in adults with obesity and SUNRISE-2 in obese or overweight
adults with type 2 diabetes. Each study is a randomized, double-blind, placebo-
controlled, multicenter trial designed to assess the efficacy and safety of oral
VK2735, with patients receiving once-daily doses for 68 weeks. SUNRISE-1 and
SUNRISE-2 are each targeting enrollment of 560 adults. Participants in each
trial will be randomized to one of four treatment groups receiving once-daily
VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.

Viking is very pleased to have these important trials underway, as it believes
oral VK2735 may represent another differentiated and high value treatment option
for patients and physicians alike.

Positive Top-Line Results Announced for Part 1 of VK2735 Maintenance Dosing
Study. Based on VK2735's promising efficacy and differentiated pharmacokinetic
(PK) profile, the company is evaluating a range of novel dosing regimens for
both the induction and the long-term maintenance of weight loss. Providing
flexible options for long-term therapy, including lower dosing and less frequent
administration, may improve treatment persistence following achievement of
individual weight loss goals. In addition, affording patients the option to
remain on the same therapeutic compound, in either a tablet or an injectable
form, throughout their treatment journey may reduce the potential for undesired
side effects compared with options that involve switching between different
therapeutic agents. The company believes this may also lead to improved
adherence to therapy and increase the probability of realizing the long-term
benefits of weight loss such as reduced cardiovascular risks, improved physical
function and enhanced quality of life.

In the third quarter the company reported positive results from Part 1 of a two-
partrange-finding study. This study, which was designed to explore a variety of
maintenance dosing regimens, demonstrated VK2735’s ability not only to achieve
significant weight loss during the induction phase, but to also maintain a high
percentage of the initial weight loss long-term using lower and less frequent
dosing regimens.

Part 1 of the maintenance study was focused on subcutaneous dosing. The novel
design incorporated multiple parts– a 21-week induction period, a 12-week
maintenance period evaluating monthly or every-other-week dosing, and a 33-week
dosing period utilizing a 17.5 mg weekly dose. A total of 180 subjects were
randomized across 11 treatment groups. Subjects were required to have a BMI ≥30
kg/m2but no other comorbidities. Induction doses ranged from 15.0 mg to 22.5 mg
per week, or placebo, administered once weekly by subcutaneous injection for 21
weeks. Following the 21-week induction period, subjects were transitioned to a
range of subcutaneous maintenance regimens, or placebo, for an additional 12
weeks.

Through the initial 21 weeks of weekly dosing, robust weight loss was observed
at all dose levels, with no signs of plateau. Week 21 weight loss ranged from
approximately 16% to approximately 19% compared with approximately 0% for
placebo. All doses clearly separated from placebo starting at Week 4, with
p-values at each dosing level less than 0.0001 compared with placebo. Among
treated subjects, 98% achieved 5% weight loss, 90% achieved 10%, 65% achieved
15%, and 32% achieved 20% weight loss. This compares well with the placebo
cohort, for which only 13% achieved 5% weight loss and none achieved 10%, 15% or
20% weight loss at Week 21. Based on the weight loss trajectories among
VK2735-treated subjects at Week 21, the company believes that further weight
loss is likely to be observed with continued dosing.

Following the 21-week induction phase of the study, subjects were transitioned
from weekly dosing to every-other-week or monthly dosing for an additional 12
weeks. Among subjects dosed every-other-week, mean weight loss retained at Week
33 ranged from 83% to 97%, compared with 61% among subjects transitioned from
17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs.
placebo. Among subjects transitioned to monthly dosing, mean weight loss
retained at Week 33 ranged from 82% to 90%, compared with 61% for placebo, with
p-values less than 0.01 for each cohort vs. placebo. The significant reduction
in weight rebound compared with placebo under either regimen demonstrated a
compelling maintenance signal, supporting the concept of less frequent dosing as
a potentially viable regimen for long-term weight management.

The maintenance study also incorporated an exploratory cohort where subjects
were maintained on a 17.5 mg weekly dose for the entire 33-week treatment
window. These participants demonstrated continued weight loss throughout the 33
week study period, reaching approximately 22% from baseline. No plateau was
observed, suggesting further weight loss might be expected with continued
dosing.

This study also demonstrated a favorable tolerability profile and low rate of
discontinuations. During the 21 week induction period, common GI adverse events
such as nausea, vomiting, diarrhea, and constipation were consistent with those
observed in the company’s prior Phase 2 VENTURE study. This is of particular
interest as these subjects were titrated faster (every two weeks) compared with
the slower titration schedule (every three weeks) used in the VENTURE study.

During the maintenance period of this study, following the transition to every-
other-week or monthly dosing, an encouraging tolerability profile was also
observed. Treatment emergent adverse events were similar to placebo, and GI-
related adverse events were low and generally no different from placebo. These
data suggest that despite a gap of up to four weeks between doses, these
participants did not resensitize to GI adverse events such as nausea or
vomiting. This supports the company’s view that VK2735’s differentiated PK
profile, with an extended half-life and excellent long-term exposures, may
provide for greater flexibility in dosing compared with existing options.

The company believes these results demonstrated a credible maintenance effect, a
key objective of the study. Importantly, results from this study will help
inform the selection of doses in the upcoming VANQUISH extension studies,
expected to begin in early 2027.
╔═ § ══════════════════════════════════════════════════════════════════════════╗
║                                                                              ║
║  Part 2 Maintenance Dosing Study Initiated, to Evaluate Oral and Additional  ║
║  Subcutaneous Regimens.                                                      ║
║                                                                              ║
╚══════════════════════════════════════════════════════════════════════════════╝
Following the successful completion of the first part of the maintenance dosing
study, the company recently initiated Part 2 of this study, designed to evaluate
a range of oral maintenance regimens, along with select subcutaneous maintenance
doses. Part 2 of the study is a randomized, double-blind, placebo-controlled
trial in approximately 195 adults with obesity(BMI ≥30 kg/m2) who are otherwise
healthy. As in Part 1, all

participants will receive initial weekly subcutaneous doses of VK2735 for 21
weeks. Following Week 21, participants will transition to a range of VK2735
maintenance dosing options including daily oral doses, monthly subcutaneous
doses, every-other-week subcutaneous doses, or placebo.Study objectives are to
evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under
these various dosing regimens. Exploratory endpoints will assess changes in body
weight from baseline and from Week 21 to the end of the study at Week 33.

The company expects the results from Part 2 of this study to be available in
2027.

Phase 1 Single Ascending Dose Study of Amylin Agonist VK3019 Nearing Completion.
VK3019 is an investigational dual amylin and calcitonin receptor agonist (DACRA)
in development for the potential treatment of obesity. P reclinical data for
this program showed robust effects on body weight, food intake, and metabolism
in healthy rats, diet-induced obese mice, and obese primates compared to
control-treated animals.

During the second quarter, the company initiateda Phase 1 single ascending dose
(SAD) clinical trialevaluating VK3019.The Phase 1 trial is a randomized, double-
blind, placebo-controlled SAD study in healthy adults with BMI ≥27. The primary
objectives of the study include an evaluation of the safety, tolerability, and
pharmacokinetics of VK3019 following administration of single subcutaneous
doses. Exploratory pharmacodynamic assessments include evaluations of changes in
body weight after a single-dose administration.

The company expects to complete the SAD study later this quarter and initiate a
4 week multiple ascending dose (MAD) study of VK3019 in 1Q27.

The addition of VK3019 to Viking’s clinical pipeline represents an important
expansion of the company’s obesity franchise and further illustrates Viking’s
commitment to treating obesity first with the goal of helping patients achieve
and maintain a weight that will allow them to improve their overall health and
quality of life.

Strong Quarter-End Cash Position of $960 Million Provides Resources to Execute
Multiple Long-Term Objectives . In September, Viking successfully closed
concurrent upsized public offerings of common stock and convertible senior
notes, resulting in gross proceeds to the company of approximately $575.0
million. Following completion of the offering, at the end of the third quarter
the company held $960 million in cash, cash equivalents and short-term
investments. In addition to providing the runway needed to reach important
milestones, including completion of the company’s ongoing Phase 3 obesity
trials, and the development of earlier stage programs, these resources will
support the company’s growing commercial operations, infrastructure and plans as
it prepares for the potential commercial launch of VK2735.

Upcoming Scientific Conference Presentations.

Viking plans to make the following presentations at scientific conferences in
the fourth quarter:
ObesityWeek; November 14 – 17, 2026 - Washington, D.C:                          
                                                                                
VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes:       
Baseline Characteristics                                                        
Saturday, November 14,2026, 7:30 pm - 8:30 pm ET

Poster presentation
Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the   
VENTURE Study                                                                   
Sunday, November 15, 2026, 2:30 pm - 3:30 pm ET
Poster presentation                                                             
Upcoming Investor Events
Viking management will participate in the following upcoming investor events:   
                                                                                
Stifel 2026 Healthcare Conference New York, NY                                  
November 10 - 12, 2026                                                          
                                                                                
Truist 2026 BioPharma Symposium New York, NY                                    
November 12, 2026                                                               
                                                                                
UBS Global Biopharma Conference                                                 
                                                                                
London, UK                                                                      
                                                                                
November 16 - 17, 2026                                                          
                                                                                
Jefferies Global Healthcare Conference                                          
                                                                                
London, UK                                                                      
                                                                                
November 16 - 19, 2026                                                          
                                                                                
Piper Sandler 38 th Annual Healthcare Conference                                
                                                                                
New York, NY                                                                    
                                                                                
December 1 – 3, 2026                                                            
                                                                                
J.P. Morgan 2027 Healthcare Conference                                          
                                                                                
San Francisco, CA                                                               
                                                                                
January 11 – 14, 2027                                                           
                                                                                
Third Quarter and Nine Months 2026 Financial Highlights                         
                                                                                
Third Quarter ended September 30, 2026, and 2025                                
Research and development expenses were $166.8 million for the three months ended
September 30, 2026, compared to $90.0 million for the same period in 2025. The
increase was primarily due to increased expenses related to planned and ongoing
clinical studies, manufacturing for the company’s drug candidates, stock-based
compensation, salaries and benefits and third-party consultants, partially
offset by decreased expenses related to preclinical studies.

General and administrative expenses were $20.3 million for the three months
ended September 30, 2026, compared to $8.6 million for the same period in 2025.
The increase was primarily due to increased expenses related to legal and patent
services, third-party consultants, stock-based compensation, and salaries and
benefits. These increases reflect the company’s rapid overall growth compared
with the same period in 2025.

For the three months ended September 30, 2026, Viking reported a net loss of
$183.2 million, or $1.55 per share, compared to a net loss of $90.8 million, or
$0.81 per share, in the corresponding period in 2025. The increase in net loss
for the three months ended September 30, 2026, was primarily due to increased
research and development expenses and general and administrative expenses, noted
previously, compared to the same period in 2025.
Nine Months ended September 30, 2026, and 2025                                  
Research and development expenses were $432.7 million for the nine months ended
September 30, 2026, compared to $191.5 million for the same period in 2025. The
increase was primarily due to increased expenses related to planned and ongoing
clinical studies, stock-based compensation, manufacturing for the company’s drug
candidates, salaries and benefits, and third-party consultants, partially offset
by decreased expenses related to preclinical studies.

General and administrative expenses were $51.1 million for the nine months ended
September 30, 2026, compared to $37.1 million for the same period in 2025. The
increase was primarily due to increased expenses related to third-party
consultants, legal and patent services, and salaries and benefits, partially
offset by decreased expenses related to stock-based compensation. These
increases reflect the company’s rapid overall growth compared with the same
period in 2025.

For the nine months ended September 30, 2026, Viking reported a net loss of
$469.5 million, or $4.03 per share, compared to a net loss of $202.0 million, or
$1.80 per share, in the corresponding period in 2025. The increase in net loss
for the nine months ended September 30, 2026, was primarily due to increased
research and development expenses and general and administrative expenses, noted
previously, compared to the same period in 2025.
Balance Sheet as of September 30, 2026                                          
At September 30, 2026, Viking held cash, cash equivalents, and short-term
investments of $960million, compared to $706 million as of December 31, 2025.
This balance includes the aggregate net proceeds of approximately $550 million
from the company’s recent financing.
Conference Call                                                                 
Management will host a conference call to discuss Viking's third quarter 2026
financial results today at 4:30 pm Eastern. To participate in the conference
call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside
the U.S. In addition, following the completion of the call, a telephone replay
will be accessible until November 4, 2026, by dialing (855) 669-9658 from the
U.S. and Canada, or (412) 317-0088 and entering conference ID #1882451. Those
interested in listening to the conference call live via the internet may do so
by visiting the Webcasts page of Viking's website at
https://ir.vikingtherapeutics.com/webcasts-presentations. An archive of the
webcast will also be available on the Webcasts page of Viking's website for 30
days.
About Viking Therapeutics, Inc.                                                 
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company
advancing a next-generation portfolio of therapies for obesity and metabolic
disease. Guided by deep expertise in metabolic biology and rigorous science,
Viking is developing innovative treatments to help people achieve meaningful,
lasting health improvements by treating obesity first. The company's lead
program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) receptor agonist in development in both
subcutaneous and oral formulations for obesity. VK2735 is currently being
evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing
strategies designed to support long-term weight management. Viking is also
advancing additional obesity programs, including VK3019, an amylin receptor
agonist, VK2809, an orally available thyroid hormone receptor beta agonist for
metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked
adrenoleukodystrophy (X-ALD).

For more information about Viking Therapeutics, please
visitwww.vikingtherapeutics.com.
Forward-Looking Statements                                                      
This press release contains forward-looking statements regarding Viking
Therapeutics, Inc., under the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including statements about Viking's
expectations regarding its clinical and preclinical development programs,
anticipated timing for reporting clinical data and cash resources. Forward-
looking statements are subject to risks and uncertainties that could cause
actual results to differ materially and adversely and reported results should
not be considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: risks associated with the
success, cost and timing of Viking's product

candidate development activities and clinical trials, including those for
VK2735, VK3019, VK0214, VK2809, and the company's other incretin and other
receptor agonists; risks that prior clinical and preclinical results may not be
replicated; risks regarding regulatory requirements; and other risks that are
described in Viking's most recent periodic reports filed with the Securities and
Exchange Commission including Viking's Annual Report on Form 10-K for the year
ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q,
including the risk factors set forth in those filings. These forward-looking
statements speak only as of the date hereof. Viking disclaims any obligation to
update these forward-looking statements except as required by law.
Viking Therapeutics, Inc. Condensed Consolidated Statements of Operations and
Comprehensive Loss (In thousands, except per share amounts) (Unaudited)
                                                                                
                Three                                Nine                       
                Mont…                               Mont…                       
                Ended                               Ended                       
                Sept…                               Sept…                       
          2026    30,       2025              2026    30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Rev…    $         —       $         —       $         —       $         —     
  Ope…                                                                          
  exp…                                                                          
  Res…                                                                          
  and           166,…             89,9…             432,…             191,…     
  dev…                                                                          
  Gen…                                                                          
  and           20,3…             8,608             51,1…             37,1…     
  adm…                                                                          
  Tot…                                                                          
  ope…          187,…             98,5…             483,…             228,…     
  exp…                                                                          
  Loss                                                                          
  from          (187…  )          (98,…  )          (483…  )          (228…  )  
  ope…                                                                          
  Oth…                                                                          
  inc…                                                                          
  (ex…                                                                          
  Amo…                                                                          
  of                —                (8  )              —               (56  )  
  fin…                                                                          
  cos…                                                                          
  Int…                                                                          
  inc…          4,014             7,772             14,3…             26,6…     
  net                                                                           
  Int…                                                                          
  exp…            (88  )              —               (88  )              —     
  net                                                                           
  Rea…                                                                          
  gain              —                10                30                14     
  on                                                                            
  inv…                                                                          
  Tot…                                                                          
  oth…          3,926             7,774             14,3…             26,6…     
  inc…                                                                          
  net                                                                           
  Net           (183…  )          (90,…  )          (469…  )          (201…  )  
  loss                                                                          
  Oth…                                                                          
  com…                                                                          
  los…                                                                          
  net                                                                           
  of                                                                            
  tax:                                                                          
  Unr…                                                                          
  (lo…                                                                          
  gain           (518  )            540             (2,0…  )          1,129     
  on                                                                            
  inv…                                                                          
  For…                                                                          
  cur…                                                                          
  tra…            (27  )              —                (9  )             33     
  (lo…                                                                          
  gain                                                                          
  Com…    $     (183…  )    $     (90,…  )    $     (471…  )    $     (200…  )  
  loss                                                                          
  Bas…                                                                          
  and                                                                           
  dil…                                                                          
  net     $     (1.55  )    $     (0.81  )    $     (4.03  )    $     (1.80  )  
  loss                                                                          
  per                                                                           
  sha…                                                                          
  Wei…                                                                          
  sha…                                                                          
  used                                                                          
  to                                                                            
  com…                                                                          
  bas…          118,…             112,…             116,…             112,…     
  and                                                                           
  dil…                                                                          
  net                                                                           
  loss                                                                          
  per                                                                           
  sha…                                                                          
                                                                                
Viking Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands,
except share and per share amounts)
                                                                                
                 September                      December                        
                 30,                            31,                             
                 2026                           2025                            
 ────────────────────────────────────────────────────────────────────────────── 
                 -Unaudited                                                     
  Assets                                                                        
  Current                                                                       
  assets:                                                                       
  Cash and                                                                      
  cash           $                677,609                    $    165,810       
  equivalents                                                                   
  Short-term                                                                    
  investments                     282,204                         539,929       
  –                                                                             
  available-…                                                                   
  Prepaid                                                                       
  clinical                                                                      
  trial and                        10,008                           8,053       
  preclinical                                                                   
  study costs                                                                   
  Prepaid                                                                       
  expenses                                                                      
  and other                         3,178                           1,806       
  current                                                                       
  assets                                                                        
  Total                                                                         
  current                         972,999                         715,598       
  assets                                                                        
  Right-of-u…                       3,853                              85       
  assets                                                                        
  Restricted                          202                               —       
  cash                                                                          
  Deposits                            113                              46       
  Total          $                977,167                    $    715,729       
  assets                                                                        
  Liabilities                                                                   
  and                                                                           
  stockholde…                                                                   
  equity                                                                        
  Current                                                                       
  liabilitie…                                                                   
  Accounts       $                 82,134                    $     53,251       
  payable                                                                       
  Other                                                                         
  accrued                          51,739                          23,279       
  liabilities                                                                   
  Lease                                                                         
  liability,                           24                             137       
  current                                                                       
  Total                                                                         
  current                         133,897                          76,667       
  liabilities                                                                   
  Lease                                                                         
  liability,                                                                    
  net of                            4,014                               —       
  current                                                                       
  portion                                                                       
  Convertible                     250,656                               —       
  Notes                                                                         
  Total                                                                         
  long-term                       254,670                               —       
  liabilities                                                                   
  Total                           388,567                          76,667       
  liabilities                                                                   
  Commitments                                                                   
  and                                                                           
  contingenc…                                                                   
  Stockholde…                                                                   
  equity:                                                                       
  Preferred                                                                     
  stock,                                                                        
  $0.00001                                                                      
  par value:                                                                    
  10,000,000                                                                    
  shares                                                                        
  authorized                                                                    
  at                                                                            
  September                                                                     
  30, 2026                                                                      
  and                                                                           
  December                              —                               —       
  31,                                                                           
  2025; no                                                                      
  shares                                                                        
  issued and                                                                    
  outstanding                                                                   
  at                                                                            
  September                                                                     
  30, 2026                                                                      
  and                                                                           
  December                                                                      
  31,                                                                           
  2025                                                                          
  Common                                                                        
  stock,                                                                        
  $0.00001                                                                      
  par value:                                                                    
  300,000,000                                                                   
  shares                                                                        
  authorized                                                                    
  at                                                                            
  September                                                                     
  30, 2026                                                                      
  and                                                                           
  December                                                                      
  31,                                                                           
  2025;                                 1                               1       
  127,521,229                                                                   
  shares                                                                        
  issued and                                                                    
  outstanding                                                                   
  at                                                                            
  September                                                                     
  30, 2026                                                                      
  and                                                                           
  114,793,067                                                                   
  shares                                                                        
  issued and                                                                    
  outstanding                                                                   
  at December                                                                   
  31, 2025                                                                      
  Additional                                                                    
  paid-in                       1,907,376                       1,486,229       
  capital                                                                       
  Accumulated                  (1,317,079  )                     (847,546    )  
  deficit                                                                       
  Accumulated                                                                   
  other                                                                         
  comprehens…                      (1,698  )                          378       
  (loss)                                                                        
  gain                                                                          
  Total                                                                         
  stockholde…                     588,600                         639,062       
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and            $                977,167                    $    715,729       
  stockholde…                                                                   
  equity                                                                        
                                                                                
Contacts:
Viking Therapeutics                                                             
                                                                                
Greg Zante                                                                      
                                                                                
Chief Financial Officer                                                         
                                                                                
858-704-4672                                                                    
                                                                                
[email protected]                                                   
                                                                                
Vida Strategic Partners                                                         
                                                                                
Stephanie Diaz (Investors)                                                      
                                                                                
415-675-7401                                                                    
                                                                                
[email protected]                                                                
                                                                                
Jennifer Arcure (Media)                                                         
                                                                                
917-603-0681                                                                    
                                                                                
[email protected]                                                              

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VKTX/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.